SML0975
FLI-06
≥98% (HPLC)
别名:
1,4,5,6,7,8-Hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylic acid cyclohexyl ester
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
2-8°C
SMILES string
[N+](=O)([O-])c1ccc(cc1)C2C3=C(NC(=C2C(=O)OC4CCCCC4)C)CC(CC3=O)(C)C
InChI
1S/C25H30N2O5/c1-15-21(24(29)32-18-7-5-4-6-8-18)22(16-9-11-17(12-10-16)27(30)31)23-19(26-15)13-25(2,3)14-20(23)28/h9-12,18,22,26H,4-8,13-14H2,1-3H3
InChI key
SWWVFYHSSOWZMF-UHFFFAOYSA-N
Biochem/physiol Actions
FLI-06 is an inhibitor of Notch signaling.
FLI-06 is an inhibitor of Notch signaling. FLI-06 acts upstream of α-secretase and β-secretase cleavage, disrupting intracellular trafficking and processing of the Notch signaling pathway and inhibiting general secretion at a step before exit from the endoplasmic reticulum (ER). This inhibition is accompanied by a tubule-to-sheet morphological transition of the ER. FLI-06 does not act on the cytoskeleton, but causes a complete disruption of the Golgi in a manner different from that of Brefeldin A or Golgicide A. FLI-06 is the first compound acting that early in the secretory pathway.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable